8-KOther Events

JOHNSON & JOHNSON 8-K Report (Dec 4, 2002)

Filed December 4, 2002For Securities:JNJ

Summary

This Form 8-K filing from Johnson & Johnson (JNJ), dated December 4, 2002, primarily announces a change in the European labeling for EPREX/ERYPO (epoetin alfa). The press release, filed as an exhibit, details this regulatory update concerning the drug's usage or warnings in the European market. While the filing itself is brief, the key takeaway for investors is the company's proactive communication regarding product labeling changes within a significant international market. Investors should note that such labeling updates can sometimes influence sales, market perception, or require adjustments in marketing strategies. Further details on the specific nature and potential impact of these labeling changes would be found within the referenced press release (Exhibit 99.15).

Key Highlights

  • 1Johnson & Johnson (JNJ) filed a Form 8-K on December 4, 2002.
  • 2The filing primarily addresses an event occurring on December 2, 2002.
  • 3The event concerns a change in European labeling for EPREX/ERYPO (epoetin alfa).
  • 4The press release detailing this change is attached as Exhibit 99.15.
  • 5This update pertains to a regulatory action or advisory in the European market.
  • 6Stephen J. Cosgrove, Chief Accounting Officer, signed the report.

Frequently Asked Questions

The main purpose of this 8-K filing is to inform the public and investors about a change in the European labeling for Johnson & Johnson's drug EPREX/ERYPO (epoetin alfa).

EPREX/ERYPO (epoetin alfa) is a pharmaceutical product manufactured by Johnson & Johnson. Epoetin alfa is a type of erythropoiesis-stimulating agent (ESA) used to treat anemia, often associated with chronic kidney disease or chemotherapy.

More specific details regarding the European labeling change for EPREX/ERYPO are available in the press release filed as Exhibit 99.15 to this Form 8-K.

This particular filing does not directly disclose financial impacts. However, changes in drug labeling, especially in major markets like Europe, can potentially influence sales, market reception, or require regulatory compliance adjustments, which could indirectly affect the company's financial performance. Investors would need to review the referenced press release and subsequent company communications for any explicit financial discussions.